Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Metzger

Cardiovascular Disease Delray Beach, FL Medical Doctor

NPI 1235253899 CMS profile 283115

13550 Jog Rd 204, Delray Beach, FL 33446

Open in the dashboard

General payments

$52,704

944 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Metzger of Delray Beach, FL is reported in the CMS Open Payments database as having received $52,704 across 944 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,002 95
2024 General $4,021 144
2023 General $12,865 126
2022 General $10,339 139
2021 General $9,225 162
2020 General $2,594 101
2019 General $11,658 177

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Metzger
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Michael Metzger were reported at $2,002. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Michael Metzger Cardiovascular Disease median Middle half National median
2019 $11,658 $450 $127–$1,392 $163
2020 $2,594 $242 $77–$751 $114
2021 $9,225 $335 $101–$1,037 $132
2022 $10,339 $395 $121–$1,211 $149
2023 $12,865 $443 $136–$1,283 $160
2024 $4,021 $450 $136–$1,323 $164
2025 $2,002 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $17,852 29 payments
  2. Inari Medical, Inc. $13,943 18 payments
  3. Penumbra, Inc. $2,407 16 payments
  4. Abbott Laboratories $2,273 89 payments
  5. Shockwave Medical, Inc $1,157 18 payments
  6. Amgen Inc. $1,131 77 payments
  7. Philips Electronics North America Corporation $1,096 6 payments
  8. Janssen Pharmaceuticals, Inc $1,073 108 payments
  9. AstraZeneca Pharmaceuticals LP $1,026 63 payments
  10. Pfizer Inc. $790 57 payments
  11. Other $9,958 463 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $21,176 920 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,000 5 payments
  3. Consulting Fee $12,400 6 payments
  4. Travel and Lodging $2,024 7 payments
  5. Education $103 6 payments
Products named General payments · program years 2019–2025
  1. CT THROMBECTOMY SYSTEM KIT $18,610 15 payments
  2. WATCHMAN $9,370 13 payments
  3. FLOWTRIEVER CATHETER, S $8,980 19 payments
  4. WATCHMAN Access System $8,046 4 payments
  5. Indigo System $2,304 15 payments
  6. Repatha $1,081 74 payments
  7. XARELTO $1,073 108 payments
  8. IGT D Peripheral $1,040 4 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $985 14 payments
  10. Impella $671 18 payments
  11. Other $15,267 723 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

6,997

Median for Cardiology: 2,533

Drug cost

$1,617,653

Median for Cardiology: $485,213

Branded share of claims

30.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 415 $470,433
Eliquis Apixaban Brand 311 $398,345
Entresto Sacubitril/Valsartan Brand 152 $211,482
Repatha Sureclick Evolocumab Brand 134 $126,076
Brilinta Ticagrelor Brand 93 $91,418
Multaq Dronedarone Hcl Brand 38 $59,811
Praluent Pen Alirocumab Brand 46 $30,214
Wegovy Semaglutide Brand 19 $25,472
Farxiga Dapagliflozin Propanediol Brand 25 $23,778
Ozempic Semaglutide Brand 15 $16,089

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$1,849,603

Of which drugs: $4,032

Medicare patients

2,684

Average age 80

Services billed

19,059

1,360 women, 1,324 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 60%
Chronic kidney disease 46%
Atrial fibrillation 41%
Diabetes 36%
Depression 34%
Heart failure 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 208 830 $4,032

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$216 146 —
CAMZYOS
$206 — —
OPSUMIT
$131 — —
VERQUVO
$117 — —
LEQVIO
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

944 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record